Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
CRISPR-based detection enables highly specific molecular recognition
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Subscribe To Our Newsletter & Stay Updated